What guidelines should be followed for chronic pain medication management?

Standards for Chronic Pain Medication Management

Follow a stepwise medication approach starting with non-opioid therapies, implement mandatory risk assessment and monitoring protocols before any opioid prescribing, and maintain routine surveillance through patient-provider agreements, urine drug testing, and prescription monitoring programs. 1

Medication Selection Algorithm

First-Line Therapy (Start Here)

For Musculoskeletal Pain:

• Acetaminophen (up to 4g/day; reduce dose in liver disease) OR NSAIDs as initial agents 1
• Acetaminophen has fewer side effects than NSAIDs
• COX-2 inhibitors reduce GI bleeding risk but increase cardiovascular risk

For Neuropathic Pain:

• Do NOT use opioids as first-line 1
• Consider gabapentin or other anticonvulsants
• Alpha lipoic acid may provide benefit 1

For Osteoarthritis:

• Tramadol 37.5-400mg daily (up to 3 months) may improve pain, stiffness, and function 1

Second/Third-Line Therapy (Only After First-Line Failure)

Opioid Consideration Criteria:

• Patient reports moderate-to-severe pain AND functional impairment 1
• First-line therapies have failed
• Benefits for pain severity, physical function, and quality of life clearly outweigh risks 1

Opioid Prescribing Rules:

• Start with the smallest effective dose
• Combine short-acting and long-acting formulations 1
• For neuropathic pain: consider morphine + gabapentin combination for additive effects 1
• Time-limited trial only 1

Mandatory Pre-Opioid Requirements

Risk Assessment (REQUIRED Before First Prescription)

Assess ALL patients for:

• Risk of misuse, diversion, and addiction 1
• Substance abuse history
• Mental health conditions (depression, anxiety)
• Previous opioid use patterns
• Social support and home safety

Screen for Depression (Ask These 2 Questions):

1. "During the past 2 weeks have you often been bothered by feeling down, depressed, or hopeless?"
2. "During the past 2 weeks have you been bothered by little interest or pleasure in doing things?" 1

If yes to either: Ask "Is this something with which you would like help?"

Opioid Patient-Provider Agreement (MANDATORY)

Must establish before prescribing: 1

• Written treatment agreement with informed consent
• Clear plan of care
• Realistic goals for pain AND function (not just pain relief)
• Patient responsibilities for medication management
• Consequences of non-adherence

Common pitfall: Never use agreement violations alone to discharge patients; consider broad differential diagnosis for behavioral changes 1

Ongoing Monitoring Standards (REQUIRED)

Routine Surveillance Tools

Check at EVERY visit:

• Prescription Drug Monitoring Program (PDMP) 1
• Pain and function scores (e.g., PEG scale)
• Evidence of clinically meaningful improvement (≥30% improvement in both pain AND function)

Periodic monitoring includes:

• Urine drug testing (UDT) - understand test limitations and when confirmatory testing needed 1
• Pill counts 1
• Assessment of adherence and side effects

Critical caveat: UDT results should NEVER be used in isolation to discharge patients; combine with other clinical data 1

Reassessment Schedule

• Initial phase: 1-4 weeks after starting opioids 2
• Maintenance: Every 3 months minimum 2
• Evaluate benefits versus harms at each visit
• Continue therapy ONLY if meaningful improvement in pain AND function 3

Safety Requirements

Patient and Family Education (MANDATORY)

Must educate on: 1

• Opioid overdose signs and symptoms
• Naloxone use for overdose reversal
• Safe storage away from others at risk
• Poison control number visibility
• Pharmacological interactions with other medications and alcohol
• Risk to household members, especially children

Naloxone prescription: Provide rescue kit and training to all patients and caregivers 1

Drug Interaction Monitoring

Know and manage common interactions: 1

• Benzodiazepines (avoid coprescribing)
• Alcohol
• Other CNS depressants
• Medications prolonging QTc interval (especially with methadone)

Dosing Thresholds

Upper limits to observe:

• Avoid doses ≥90-200 morphine milligram equivalents (MME) per day 4
• Do not prescribe extended-release/long-acting opioids initially 2
• If dose escalation needed, increase cautiously with enhanced monitoring

Methadone-specific rules:

• Requires additional prescriber knowledge 4
• Split dosing every 6-8 hours for analgesia (not once-daily) 1
• Monitor QTc intervals due to cardiac risks 1

When to Discontinue or Taper

Stop or taper if:

• No clinically meaningful improvement in pain AND function
• Serious adverse events occur
• Evidence of misuse, diversion, or addiction develops
• Patient requests discontinuation
• Risks outweigh benefits

Tapering protocol:

• Reduce by at least 25-50% when switching opioids 4
• Gradual taper to avoid withdrawal
• Never use rapid forced tapers (associated with increased hospitalizations and mental health crises) 5

Documentation Standards

Document at each visit:

• Pain and function scores with comparison to baseline
• Adherence monitoring results (PDMP, UDT, pill counts)
• Side effects and adverse events
• Functional status changes
• Justification for continuing therapy
• Any modifications to treatment plan

This structured approach prioritizes patient safety while allowing appropriate pain management for those with genuine medical necessity and demonstrated benefit.